Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.

Abstract

Venetoclax (ABT-199/GDC-0199) is a selective first-in-class B cell lymphoma-2 inhibitor being developed for the treatment of hematological malignancies. The aim of this study was to determine the potential of venetoclax to prolong the corrected QT (QTc) interval and to evaluate the relationship between systemic venetoclax concentration and QTc interval. The study population included 176 male and female patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (n=105) or non-Hodgkin's lymphoma (n=71) enrolled in a phase 1 safety, pharmacokinetic, and efficacy study. Electrocardiograms were collected in triplicate at time-matched points (2, 4, 6, and 8h) prior to the first venetoclax administration and after repeated venetoclax administration to achieve steady state conditions. Venetoclax doses ranged from 100 to 1200mg daily. Plasma venetoclax samples were collected after steady state electrocardiogram measurements. The mean and upper bound of the 2-sided 90% confidence interval (CI) QTc change from baseline were <5 and <10ms, respectively, at all time points and doses (<400, 400, and >400mg). Three subjects had single QTc values >500ms and/or ΔQTc>60ms. The effect of venetoclax concentration on both ΔQTc and QTc was not statistically significant (P>0.05). At the mean maximum concentrations achieved with therapeutic (400mg) and supra-therapeutic (1200mg) venetoclax doses, the estimated drug effects on QTc were 0.137 (90% CI [-1.01 to 1.28]) and 0.263 (90% CI [-1.92 to 2.45])ms, respectively. Venetoclax does not prolong QTc interval even at supra-therapeutic doses, and there is no relationship between venetoclax concentrations and QTc interval.